Myasthenia Gravis Trial, Recruiting (NCT07595653)

Myasthenia Gravis Trial, Recruiting NCT07595653 Sponsor: argenx Condition: Myasthenia Gravis

Printed from Voxsanity (voxsanity.com.au) — NCT07595653 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Myasthenia Gravis

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You are at least 18 years old at the time of signing the consent and privacy forms
You have been officially diagnosed with generalized Myasthenia Gravis (a muscle weakness condition that affects the whole body)
Your blood tests have shown that you have a specific antibody called AChR-antibody, which is linked to your condition
Your doctor has already independently decided to start you on a medication called efgartigimod alfa as part of your normal medical care, following the approved guidelines for that medicine

Who may not be able to join:

You have had an allergic reaction or sensitivity to efgartigimod alfa or any of its ingredients, which include: sodium dihydrogen phosphate monohydrate, disodium hydrogen phosphate anhydrous, arginine hydrochloride, polysorbate 80, hyaluronidase, histidine, histidine hydrochloride monohydrate, methionine, polysorbate 20, or sucrose (confirm with trial site if you are unsure about any of these)
You are currently taking part in, or are planning to take part in, another clinical trial that involves a treatment or intervention

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 28 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 857-350-4834

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT07595653

Sponsor: argenx

Phase: Not Applicable

Status: Recruiting

Condition: Myasthenia Gravis

Trial contact: 857-350-4834

More information: https://clinicaltrials.gov/study/NCT07595653

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You are at least 18 years old at the time of signing the consent and privacy forms
You have been officially diagnosed with generalized Myasthenia Gravis (a muscle weakness condition that affects the whole body)
Your blood tests have shown that you have a specific antibody called AChR-antibody, which is linked to your condition
Your doctor has already independently decided to start you on a medication called efgartigimod alfa as part of your normal medical care, following the approved guidelines for that medicine

Who may not be able to join:

You have had an allergic reaction or sensitivity to efgartigimod alfa or any of its ingredients, which include: sodium dihydrogen phosphate monohydrate, disodium hydrogen phosphate anhydrous, arginine hydrochloride, polysorbate 80, hyaluronidase, histidine, histidine hydrochloride monohydrate, methionine, polysorbate 20, or sucrose (confirm with trial site if you are unsure about any of these)
You are currently taking part in, or are planning to take part in, another clinical trial that involves a treatment or intervention

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 28 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

argenx

Registry

ClinicalTrials.gov

Start date

25 February 2026

Est. completion

1 November 2027

Where this trial is recruiting

🇮🇹 Italy

Primary endpoints

Changes in MG-ADL scores from baseline; Percentage of patients achieving MSE

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov